JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

Search

Glaukos Corp

Open

SectorGezondheidszorg

118.77 -4.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

118.33

Max

123.38

Belangrijke statistieken

By Trading Economics

Inkomsten

3.4M

-16M

Verkoop

9.4M

134M

EPS

-0.16

Winstmarge

-12.155

Werknemers

995

EBITDA

8.1M

-570K

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+10.46% upside

Dividenden

By Dow Jones

Volgende Winsten

17 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.8B

7.1B

Vorige openingsprijs

122.99

Vorige sluitingsprijs

118.77

Nieuwssentiment

By Acuity

23%

77%

40 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 jan 2026, 18:25 UTC

Belangrijke Marktbewegers

Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

10.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 136.91 USD  10.46%

Hoogste 165 USD

Laagste 120 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technische score

By Trading Central

87.61 / 93Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

40 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat